Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Bethesda North Marriott Hotel and Conference Center

Sep 17, 2015 7:15 AM - Sep 18, 2015 4:15 PM

5701 Marinelli Road, , North Bethesda, MD 20852 , USA

Patient Engagement in Benefit-Risk Assessment throughout the Life Cycle of Medical Products

Engage with patients, industry, and regulators to address the challenges of when and how to include patient perspectives in benefit-risk assessment of medical products.

Session 3: Learnings from Patient Engagement in Clinical Trials and Other Types of Health Research

Session Chair(s)

John F. P. Bridges, PhD

John F. P. Bridges, PhD

Professor, Departments of Biomedical Informatics

Ohio State University College of Medicine, United States

K. Kimberly  McCleary

K. Kimberly McCleary

Founder and Chief Executive Officer

The Kith Collective, LLC, United States

Awareness of the importance of patient engagement in benefit-risk assessment and decision-making is growing, but there is still limited evidence about effective engagement practices. This session focuses on patient engagement in other aspects of the clinical trial, such as the qualification of patient-reported outcome measures (PROs), and in other types of health research, such as PCORI-funded research, and what can be learned from those experiences.

Speaker(s)

Darius  Tandon, PhD

Panel Discussion

Darius Tandon, PhD

Northwestern University, United States

Ari  Gnanasakthy, MBA, MS, MSc

Ari Gnanasakthy, MBA, MS, MSc

Novartis Pharmaceuticals Corporation, United States

Head, Patient Reported Outcomes

Susan  DosReis, PhD

Susan DosReis, PhD

University of Maryland School of Pharmacy, United States

Associate Professor, Dept. of Pharmaceutical Health Services Research

Panel  Q&A

Panel Q&A

United States

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.